Lymphoma, Non Hodgkin Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Recruiting
  • Acute Lymphoid Leukemia
  • +4 more
  • CD19/CD22 CAR T-Cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
N
Recruiting
  • Multiple Myeloma
  • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    2022-04-07
    Apr 7, 2022
    E
    Recruiting
    • Leukemia, Lymphoid
    • +6 more
    • Wuhu, Anhui, China
    • +21 more
    2022-04-06
    Apr 6, 2022
    N
    Recruiting
    • Hodgkin Disease
    • +4 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      2022-04-07
      Apr 7, 2022
      N
      Completed
      • Leukemia
      • +3 more
        • Bethesda, Maryland
          National Cancer Institute (NCI), 9000 Rockville Pike
        2022-04-07
        Apr 7, 2022
        C
        Recruiting
        • Lymphoma, Non-Hodgkin
        • +6 more
        • CB-010
        • +2 more
        • Scottsdale, Arizona
        • +5 more
        2022-04-05
        Apr 5, 2022
        P
        Enrolling by invitation
        • Lymphoma, B-Cell
        • +4 more
        • Burbank, California
        • +90 more
        2022-03-31
        Mar 31, 2022
        A
        Recruiting
        • Advanced Solid Tumor
        • +9 more
        • Phoenix, Arizona
        • +20 more
        2022-03-31
        Mar 31, 2022
        J
        Completed
        • Lymphoma, Non-Hodgkin
        • Obinutuzumab and Pixantrone
        • Mainz, RLP, Germany
          Department of Hematology, Oncology and Pneumology; University Me
        2022-03-30
        Mar 30, 2022
        B
        Active, not recruiting
        • Lymphoma, Non-Hodgkin
        • Copanlisib (BAY 80-6946)
        • Jaú, Sao Paulo, Brazil
        • +20 more
        2022-03-25
        Mar 25, 2022
        J
        Recruiting
        • Lymphoma, Non-Hodgkin
        • Leukemia, Lymphocytic, Chronic, B-Cell
        • Birmingham, Alabama
        • +34 more
        2022-03-24
        Mar 24, 2022
        J
        Recruiting
        • Lymphoma, Non-Hodgkin
        • Leukemia, Lymphocytic, Chronic, B-Cell
        • New York, New York
        • +15 more
        2022-03-24
        Mar 24, 2022
        J
        Recruiting
        • Leukemia, Lymphocytic, Chronic, B-Cell
        • Lymphoma, Non-Hodgkin
        • Duarte, California
        • +49 more
        2022-03-24
        Mar 24, 2022
        J
        Recruiting
        • Leukemia, Lymphocytic, Chronic, B-Cell
        • Lymphoma, Non-Hodgkin
        • New York, New York
        • +33 more
        2022-03-24
        Mar 24, 2022
        J
        Recruiting
        • Lymphoma, Non-Hodgkin
        • Chronic Lymphocytic Leukemia
        • New York, New York
        • +34 more
        2022-03-24
        Mar 24, 2022
        B
        Active, not recruiting
        • Lymphoma, Non-Hodgkin
        • Copanlisib (BAY80-6946)
        • +7 more
        • Chandler, Arizona
        • +200 more
        2022-03-23
        Mar 23, 2022
        E
        Recruiting
        • Leukemia, Lymphocytic, Chronic, B-Cell
        • +6 more
        • Miami, Florida
        • +4 more
        2022-03-07
        Mar 7, 2022
        C
        Recruiting
        • Lymphoma, Non-Hodgkin
        • +2 more
        • Edmonton, Alberta, Canada
        • +9 more
        2022-03-14
        Mar 14, 2022
        U
        Active, not recruiting
        • Hodgkin Disease
        • +8 more
        • ATLCAR.CD30 cells
        • Chapel Hill, North Carolina
        • +1 more
        2022-03-02
        Mar 2, 2022